NCT04082390 is a NA clinical trial of RELEASE in Diabetes Mellitus, Type 2, sponsored by Golo.

Who is sponsoring NCT04082390?

NCT04082390 is sponsored by Golo.

What drugs are being tested in NCT04082390?

Interventions in NCT04082390: RELEASE, Placebo.

What condition does NCT04082390 study?

NCT04082390 studies Diabetes Mellitus, Type 2.

Is NCT04082390 still recruiting?

NCT04082390 is currently status unknown. Last updated 9 September 2019.

Last reviewed 2019-09-09 · How we verify

NCT04082390

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of the GOLO for Life System Diet With and Without GOLO Release Supplement on Glycemic Control and Insulin Resistance

Status unknown NA Last updated 9 September 2019

What this trial tests

NA trial testing RELEASE in Diabetes Mellitus, Type 2 in 36 participants. Status unknown.

Timeline

1 October 2019

Primary endpoint
30 January 2020

31 January 2020

Quick facts

Lead sponsor	Golo
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	36
Start date	1 October 2019
Primary completion	30 January 2020
Estimated completion	31 January 2020

Drugs / interventions tested

RELEASE
Placebo

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Golo

Who can join

Adults 18 to 80, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized, double-blind placebo-controlled study is intended to observe the short-term effects of the GFL System Diet with Release supplement versus GFL System Diet with placebo on glycemic metabolism and insulin resistance in patients with Type 2 DM.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Golo trials

Trials by the same sponsor.

NCT05844631 — The Effects of the GOLO for Life® Plan and Release Supplement on Weight Management in Overweight and Obese Adults · Phase 2 · completed
NCT03842501 — Effects of the GOLO Weight Management Program With and Without Release Supplement on Weight and Metabolic Parameters in · Phase 3 · completed
NCT03478202 — GOLO Open-Label Pilot 1 · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04082390 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Golo
Last refreshed: 9 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04082390.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing